Spear Chucker Jones - MASH
CORONA Problems with J&J vaccine?
- Thread starter bev
- Start date
Cyclonemom
Veteran Member
Just heard on TV news.
J&J vaccine now paused due to low platelet count blood clots.
Looking for article
ETA sauce
abcnews.go.com
US recommends 'pause' for J&J vaccine over clot reports
The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots
By ZEKE MILLER Associated Press
April 13, 2021, 6:30 AM
• 1 min read
The Associated Press
Restaurant workers and restaurant delivery workers wait in line to sign up for Johnson & Johnson's COVID-1...Read More
WASHINGTON -- The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.
In a joint statement Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration said it was investigating clots in six women in the days after vaccination, in combination with reduced platelet counts. More than 6.8 million doses of the J&J vaccine have been administered in the U.S.
U.S. federal distribution channels, including mass vaccination sites, will pause the use of the J&J shot, and states and other providers are expected to follow.
CDC's Advisory Committee on Immunization Practices will meet Wednesday to discuss the cases and the FDA has also launched an investigation of the cases.
“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said in a joint statement.
J&J vaccine now paused due to low platelet count blood clots.
Looking for article
ETA sauce
US recommends 'pause' for J&J shots in blow to vaccine drive
The U.S. recommendation to “pause” use of the single-dose Johnson & Johnson COVID-19 vaccine set off a chain reaction worldwide and dealt a setback to the global vaccine campaign
abcnews.go.com
US recommends 'pause' for J&J vaccine over clot reports
The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots
By ZEKE MILLER Associated Press
April 13, 2021, 6:30 AM
• 1 min read
Restaurant workers and restaurant delivery workers wait in line to sign up for Johnson & Johnson's COVID-1...Read More
WASHINGTON -- The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.
In a joint statement Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration said it was investigating clots in six women in the days after vaccination, in combination with reduced platelet counts. More than 6.8 million doses of the J&J vaccine have been administered in the U.S.
U.S. federal distribution channels, including mass vaccination sites, will pause the use of the J&J shot, and states and other providers are expected to follow.
CDC's Advisory Committee on Immunization Practices will meet Wednesday to discuss the cases and the FDA has also launched an investigation of the cases.
“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said in a joint statement.
Cyclonemom
Veteran Member
Your friend is a good source. Keep her around!!
Cyclonemom
Veteran Member
Another article
www.nytimes.com
WASHINGTON — Federal health agencies on Tuesday called for an immediate pause in use of Johnson & Johnson’s single-dose coronavirus vaccine after six recipients in the United States developed a rare disorder involving blood clots within about two weeks of vaccination.
All six recipients were women between the ages of 18 and 48. One woman died and a second woman in Nebraska has been hospitalized in critical condition.
Nearly seven million people in the United States have received Johnson & Johnson shots so far, and roughly nine million more doses have been shipped out to the states, according to data from the Centers for Disease Control and Prevention.
“We are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, and Dr. Anne Schuchat, principal deputy director of the C.D.C., said in a joint statement. “Right now, these adverse events appear to be extremely rare.”
While the move was framed as a recommendation to health practitioners in the states, the federal government is expected to pause administration of the vaccine at all federally run vaccination sites. Federal officials expect that state health officials will take that as a strong signal to do the
Scientists with the F.D.A. and C.D.C. will jointly examine possible links between the vaccine and the disorder and determine whether the F.D.A. should continue to authorize use of the vaccine for all adults or limit the authorization. An emergency meeting of the C.D.C.’s outside advisory committee has been scheduled for Wednesday.
The move could substantially complicate the nation’s vaccination efforts at a time when many states are confronting a surge in new cases and seeking to address vaccine hesitancy. Regulators in Europe and elsewhere are concerned about a similar issue with another coronavirus vaccine, developed by AstraZeneca and Oxford University researchers. That concern has driven up some resistance to all vaccines, even though the AstraZeneca version has not been authorized for emergency use in the United States.
The vast majority of the nation’s vaccine supply comes from two other manufacturers, Pfizer-BioNTech and Moderna, which together deliver more than 23 million doses a week of their two-shot vaccines. There have been no significant safety concerns about either of those vaccines.
But while shipments of the Johnson & Johnson vaccine have been much more limited, the Biden administration had still been counting on using hundreds of thousands of doses every week. In addition to requiring only a single dose, the vaccine is easier to ship and store than the other two, which must be stored at extremely low temperatures.
It is unclear to what degree the pause in the use of the Johnson & Johnson vaccine will set back the Biden administration’s plans to deliver enough vaccine to be able to inoculate all adults in the United States by the end of May.
Federal officials are concerned that doctors may not be trained to look for the rare disorder if recipients of the vaccine develop symptoms of it. The federal health agencies said Tuesday morning that “treatment of this specific type of blood clot is different from the treatment that might typically be administered” for blood clots.
“Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given,” the statement said.
In a news release, Johnson & Johnson said: “We are aware that thromboembolic events including those with thrombocytopenia have been reported with Covid-19 vaccines. At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.” Janssen is the name of Johnson & Johnson’s division that developed the vaccine.
In the United States alone, 300,000 to 600,000 people a year develop blood clots, according to C.D.C. data. But the particular blood clotting disorder that the vaccine recipients developed, known as cerebral venous sinus thrombosis, is extremely rare.
All of the women developed the condition within about two weeks of vaccination, and government experts are concerned that an immune system response triggered by the vaccine was the cause.
The decision is a fresh blow both to Johnson & Johnson and to the administration’s plans. Late last month, the company discovered that workers at a Baltimore plant run by its subcontractor had accidentally contaminated a batch of vaccine, forcing the firm to throw out the equivalent of 13 million to 15 million doses. That plant was supposed to take over supply of the vaccine to the United States from Johnson & Johnson’s Dutch plants, which were certified by federal regulators earlier this year.
The Baltimore plant’s certification by the F.D.A. has now been delayed while inspectors investigate quality control issues, sharply reducing the supply of Johnson & Johnson vaccine. The sudden drop in available doses led to widespread complaints from governors and state health officials who had been expecting much bigger shipments of Johnson & Johnson’s vaccine this week than they got.
States have been using the vaccine in a broad range of settings, including at mass vaccination sites and on college campuses. The vaccine’s one-shot approach has proved popular, and officials have directed it to transient, rural and isolated communities where following up with a second dose is more complicated.
It is common for regulators to investigate “safety signals” in new vaccines and other medical products. Very often, the signals prove not to be of concern. But the concerns about Johnson & Johnson’s vaccine mirror concerns about AstraZeneca’s, which European regulators began investigating last month after some recipients developed blood clots.
Out of 34 million people who received the vaccine in Britain, the European Union and three other countries, 222 experienced blood clots that were linked with a low level of platelets. The majority of these cases occurred within the first 14 days following vaccination, mostly in women under 60 years of age.
On April 7, the European Medicines Agency, the main regulatory agency, concluded that the disorder was a very rare side effect of the vaccine. Researchers in Germany and Norway published studies on April 9 suggesting that in very rare cases, the AstraZeneca vaccine caused people to make antibodies that activated their own platelets.
Nevertheless, the regulators argued, the benefit of the vaccine — keeping people from being infected with the coronavirus or keeping those few who get Covid-19 out of the hospital — vastly outweighed that small risk. Countries in Europe and elsewhere continued to give the vaccine to older people, who face a high risk of severe disease and death from Covid-19, while restricting it in younger people.
Both AstraZeneca and Johnson & Johnson use the same platform for their vaccine, a virus known as an adenovirus. On Tuesday, the Australian government announced it would not purchase Johnson & Johnson vaccines. They cited Johnson & Johnson’s use of an adenovirus. But there is no obvious reason adenovirus-based vaccines in particular would cause rare blood clots associated with low platelet levels.
AstraZeneca has not yet applied for an emergency use authorization in the United States.
The Moderna and Pfizer-BioNTech vaccines use a different technology to produce immunity.
The first sign of concern about Johnson & Johnson’s vaccine came on April 9, when the European Medicines Agency announced that it was investigating reports of four cases of blood clots in people who received the Johnson & Johnson vaccine in the United States. One case occurred in the clinical trial that took place before the vaccine was authorized. Three occurred in the vaccine rollout. One of them was fatal, the agency said.
The regulators described these reports as a “safety signal” — a cluster of cases requiring further investigation. But they said it wasn’t clear if the vaccines caused the clots.
Johnson & Johnson responded with a statement saying, “At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.”
Johnson & Johnson Vaccinations Paused After Rare Clotting Cases Emerge
Federal health officials called for a halt in the use of the company’s coronavirus vaccine while they study serious illnesses that developed in six American women.
WASHINGTON — Federal health agencies on Tuesday called for an immediate pause in use of Johnson & Johnson’s single-dose coronavirus vaccine after six recipients in the United States developed a rare disorder involving blood clots within about two weeks of vaccination.
All six recipients were women between the ages of 18 and 48. One woman died and a second woman in Nebraska has been hospitalized in critical condition.
Nearly seven million people in the United States have received Johnson & Johnson shots so far, and roughly nine million more doses have been shipped out to the states, according to data from the Centers for Disease Control and Prevention.
“We are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, and Dr. Anne Schuchat, principal deputy director of the C.D.C., said in a joint statement. “Right now, these adverse events appear to be extremely rare.”
While the move was framed as a recommendation to health practitioners in the states, the federal government is expected to pause administration of the vaccine at all federally run vaccination sites. Federal officials expect that state health officials will take that as a strong signal to do the
Scientists with the F.D.A. and C.D.C. will jointly examine possible links between the vaccine and the disorder and determine whether the F.D.A. should continue to authorize use of the vaccine for all adults or limit the authorization. An emergency meeting of the C.D.C.’s outside advisory committee has been scheduled for Wednesday.
The move could substantially complicate the nation’s vaccination efforts at a time when many states are confronting a surge in new cases and seeking to address vaccine hesitancy. Regulators in Europe and elsewhere are concerned about a similar issue with another coronavirus vaccine, developed by AstraZeneca and Oxford University researchers. That concern has driven up some resistance to all vaccines, even though the AstraZeneca version has not been authorized for emergency use in the United States.
The vast majority of the nation’s vaccine supply comes from two other manufacturers, Pfizer-BioNTech and Moderna, which together deliver more than 23 million doses a week of their two-shot vaccines. There have been no significant safety concerns about either of those vaccines.
But while shipments of the Johnson & Johnson vaccine have been much more limited, the Biden administration had still been counting on using hundreds of thousands of doses every week. In addition to requiring only a single dose, the vaccine is easier to ship and store than the other two, which must be stored at extremely low temperatures.
It is unclear to what degree the pause in the use of the Johnson & Johnson vaccine will set back the Biden administration’s plans to deliver enough vaccine to be able to inoculate all adults in the United States by the end of May.
Federal officials are concerned that doctors may not be trained to look for the rare disorder if recipients of the vaccine develop symptoms of it. The federal health agencies said Tuesday morning that “treatment of this specific type of blood clot is different from the treatment that might typically be administered” for blood clots.
“Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given,” the statement said.
In a news release, Johnson & Johnson said: “We are aware that thromboembolic events including those with thrombocytopenia have been reported with Covid-19 vaccines. At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.” Janssen is the name of Johnson & Johnson’s division that developed the vaccine.
In the United States alone, 300,000 to 600,000 people a year develop blood clots, according to C.D.C. data. But the particular blood clotting disorder that the vaccine recipients developed, known as cerebral venous sinus thrombosis, is extremely rare.
All of the women developed the condition within about two weeks of vaccination, and government experts are concerned that an immune system response triggered by the vaccine was the cause.
The decision is a fresh blow both to Johnson & Johnson and to the administration’s plans. Late last month, the company discovered that workers at a Baltimore plant run by its subcontractor had accidentally contaminated a batch of vaccine, forcing the firm to throw out the equivalent of 13 million to 15 million doses. That plant was supposed to take over supply of the vaccine to the United States from Johnson & Johnson’s Dutch plants, which were certified by federal regulators earlier this year.
The Baltimore plant’s certification by the F.D.A. has now been delayed while inspectors investigate quality control issues, sharply reducing the supply of Johnson & Johnson vaccine. The sudden drop in available doses led to widespread complaints from governors and state health officials who had been expecting much bigger shipments of Johnson & Johnson’s vaccine this week than they got.
States have been using the vaccine in a broad range of settings, including at mass vaccination sites and on college campuses. The vaccine’s one-shot approach has proved popular, and officials have directed it to transient, rural and isolated communities where following up with a second dose is more complicated.
It is common for regulators to investigate “safety signals” in new vaccines and other medical products. Very often, the signals prove not to be of concern. But the concerns about Johnson & Johnson’s vaccine mirror concerns about AstraZeneca’s, which European regulators began investigating last month after some recipients developed blood clots.
Out of 34 million people who received the vaccine in Britain, the European Union and three other countries, 222 experienced blood clots that were linked with a low level of platelets. The majority of these cases occurred within the first 14 days following vaccination, mostly in women under 60 years of age.
On April 7, the European Medicines Agency, the main regulatory agency, concluded that the disorder was a very rare side effect of the vaccine. Researchers in Germany and Norway published studies on April 9 suggesting that in very rare cases, the AstraZeneca vaccine caused people to make antibodies that activated their own platelets.
Nevertheless, the regulators argued, the benefit of the vaccine — keeping people from being infected with the coronavirus or keeping those few who get Covid-19 out of the hospital — vastly outweighed that small risk. Countries in Europe and elsewhere continued to give the vaccine to older people, who face a high risk of severe disease and death from Covid-19, while restricting it in younger people.
Both AstraZeneca and Johnson & Johnson use the same platform for their vaccine, a virus known as an adenovirus. On Tuesday, the Australian government announced it would not purchase Johnson & Johnson vaccines. They cited Johnson & Johnson’s use of an adenovirus. But there is no obvious reason adenovirus-based vaccines in particular would cause rare blood clots associated with low platelet levels.
AstraZeneca has not yet applied for an emergency use authorization in the United States.
The Moderna and Pfizer-BioNTech vaccines use a different technology to produce immunity.
The first sign of concern about Johnson & Johnson’s vaccine came on April 9, when the European Medicines Agency announced that it was investigating reports of four cases of blood clots in people who received the Johnson & Johnson vaccine in the United States. One case occurred in the clinical trial that took place before the vaccine was authorized. Three occurred in the vaccine rollout. One of them was fatal, the agency said.
The regulators described these reports as a “safety signal” — a cluster of cases requiring further investigation. But they said it wasn’t clear if the vaccines caused the clots.
Johnson & Johnson responded with a statement saying, “At present, no clear causal relationship has been established between these rare events and the Janssen Covid-19 vaccine.”
intothatgoodnight
. . .
Interesting that the only "vaccines" left on the market are mRNA-types?
intothegoodnight
intothegoodnight
inskanoot
Veteran Member
Uh huh.
No nice way to respond to this nugget.Well there is, but I don’t want to. Right now.
Last edited:
night driver
ESFP adrift in INTJ sea
In answer to the thread headline:
Not yet.
Not yet.
THANK YOU! Hate when my cultural references are only partial.
Yes. She can be very accurate on a number of subjects. She can be a wee scary. lol
Donghe Surfer
Veteran Member
I thought only J&J vaccinn was the "one" to get, because it was 1-shot AND its formula was not like AZ, Moderna, and Pfizer, as it does not have ability to change DNA/RNA. Am i wrong in this statement? If not wrong, then what's left to safely get? Just curious. What a snafu.
Border Collie Dad
Flat Earther
This presents a bit of a pickle to those vaxxers that want a shot but won't take the mRNA ones.
What to do?
What to do?
What to do?
What to do?
Profit of Doom
Dismember
Get some IVM and appropriate supplements for treatment if you catch it. Prophylactic with HCQ or quercetin.
MinnesotaSmith
Membership Revoked
Anyone hearing any whispers on when the little ones are likely to start getting pusedinto taking the fauxines?
intothatgoodnight
. . .
Don't take the mRNA-type vaccines.
Instead, bump the supplements that are known to boost your immune system against a "COVID" infection.
Do it NOW. Do not hesitate. Every day - do not miss a day.
Prophylaxis "COVID" dosing regimes/schedules have been published here, on TB2K several times, as well as elsewhere.
Vitamin D3
Magnesium
Vitamin C (ideally in liposomal form)
Zinc
Selenium
Quercetin
Standard dose of other vitamins and supplements - A, B-family, chromium, boron come to mind, but certainly not all that need paying attention to, every day. A good multi-vitamin can be an answer, here. Read the labels. Know the doses.
In addition, have azrithomycin and/or doxycycline, as well as HCQ and/or Ivermectin standing by, and know when/how/what dosage cycle to administer early, in order to lessen the physical effects of a "COVID" episode, and reduce the chances of a "COVID" hospital admission.
Take charge and responsibility for your own health, with regards to all-things-"COVID." Knowledge is KEY. Make the effort to gain that knowledge, and stay informed/light on your feet as the alternative treatment narrative shifts/changes, and more treatment details emerge/become known.
The "COVID" message is purposefully muddied and politicized by many/most MSM/CDC sources - often, J6P folks are being outright lied to - directly, or indirectly - regarding "COVID" - know how to peer through this artificially created phog of propaganda, to see the better/correct path.
There is a live narrative-shaping exercise afoot, and J6P IS THE TARGET.
intothegoodnight
Last edited:
Border Collie Dad
Flat Earther
I don't take vaccines.
Just poking a little fun at those who do.
In other words, being an ass.
We pretty much know that by now.
Border Collie Dad
Flat Earther
Just making sure
goosebeans
Veteran Member
That was my neighbor's response when I said I was holding off because these vaccines had been pushed through awful quick. She's an RN, but replied "Oh I knooow, but we really need to get this country back up and running again, it's just been too long"
Morons abound.
TammyinWI
Talk is cheap
Now the other two need to be stopped, too!
inskanoot
Veteran Member
On main coronavirus thread: COVID vaccine and prion disease, among other things.
www.timebomb2000.com
CORONA - Main Coronavirus thread
At some point, only the willfully ignorant and destructive will remain unvaccinated. From post 53638 Question. Is "Willfully ignorant and destructive" worse than racist? Cause I'm tired of being called racist, especially when I'm not. But I have no problem with willfully ignorant and...
Ah. We call these people “one of those” in my RN circle. Lol. And bless their hearts.
EVERYONE is entitled to their choice/opinion. No problem. I do not laugh at them for taking the “vax” and wish them well.
However, we are already hearing of shot 3&4. And that means something to me: you have NOT been released to anything yet. So, “my circle” waits. Too many unknowns for me to jump on this wagon right now.